Recent clinical successes in immuno-oncology have highlighted the important role the immune system can play in the destruction of human tumors. In this webinar, you’ll learn how modelling aspects of the tumor microenvironment (TME) can guide development of novel immune-modulating cancer therapies.

  • As the range of therapeutic targets grows, there is a clear need for bespoke assay systems that model different aspects of the TME.
  • In vitro human cell biology assays can be supplemented with in vivo PD and efficacy models, where anti-tumor immunity can be assessed.
  • As projects move into the clinic, careful validation of efficacy/PD and immunotoxicology biomarkers plays a critical role in adding value.


  • Prof. Neil Williams, PhD, Senior Director of Immunology, Discovery Services, Charles River